Throne Biotechnologies Wins '5 Best BioTech Companies To Watch' Award From The Silicon Review
March 28, 2022 09:00 ET | Throne Biotechnologies Inc
PARAMUS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Throne Biotechnologies (Throne), one of the global-leading biotech companies aiming to find a cure for type 1 diabetes and other autoimmune...
researchdrivelogo.jpg
Global Digital therapeutics Market to Perceive Noteworthy Growth Due to Growing Cases of Chronic Disorders Worldwide [175-Pages] | Divulge by Research Dive
March 21, 2022 09:03 ET | Research Dive
New York, USA, March 21, 2022 (GLOBE NEWSWIRE) -- A new report on the global digital therapeutics market has been added by Research Dive to its repository. As per the report, the market is expected...
NCQA Resets Diabetes Programs to Improve Outcomes
March 16, 2022 12:15 ET | NCQA
WASHINGTON, March 16, 2022 (GLOBE NEWSWIRE) -- The National Committee for Quality Assurance (NCQA) announced a major update for its Diabetes Recognition Program. It also revealed plans to develop...
Hospitals have a New Option for Glycemic Management Program Certification
March 15, 2022 12:39 ET | DNV Healthcare USA Inc.
Cincinnati, OH, March 15, 2022 (GLOBE NEWSWIRE) -- DNV Healthcare USA Inc. announced the launch of a new program to validate excellence in the management of glycemic control in hospitals - Glycemic...
eyenuk_logo_redesign_2017_onecolor.png
Eyenuk Joins the Population Health Alliance, Paving Way for Autonomous AI to Improve Diabetes Complications
March 10, 2022 08:00 ET | Eyenuk, Inc.
WASHINGTON, March 10, 2022 (GLOBE NEWSWIRE) -- Population Health Alliance (PHA), the industry’s only multi-stakeholder professional and trade association solely focused on population health,...
Happy Bob Integrates With Dexcom CGM to Provide a Playful Way to Engage With Real-Time Glucose Values and Improve Overall Self-Care
March 08, 2022 07:00 ET | Harald AI
HELSINKI, March 08, 2022 (GLOBE NEWSWIRE) -- Diabetes tech startup Harald AI today introduced a more expansive way for Dexcom Continuous Glucose Monitoring (CGM) System users to engage with their...
 Inventiva announces that its IND application for the Phase II combination trial with lanifibranor and empagliflozin in patients with NASH and T2D has been accepted by the FDA
March 08, 2022 02:00 ET | INVENTIVA
FDA assessment concludes that the Phase II combination trial, LEGEND, may proceed The initiation of the trial is planned for H1 2022 and the publication of topline results is expected for H2 2023 ...
Inventiva annonce que la FDA accepte sa demande d’« Investigational New Drug » pour l’essai clinique de Phase II combinant lanifibranor et empagliflozine chez des patients atteints de la NASH et de diabète de type 2
March 08, 2022 02:00 ET | INVENTIVA
L’évaluation de la Food and Drug Administration (FDA) est favorable à la poursuite de l’essai clinique combiné LEGEND Le lancement de l’étude est prévu pour S1 2022 et la publication des premiers...
BB_Stacked_BW_TM_RGB.jpg
Beta Bionics Announces Executive Leadership and Board Transitions in Preparation for Commercialization of the iLet® Bionic Pancreas System
March 02, 2022 16:15 ET | Beta Bionics, Inc.
Caution: The iLet® Bionic Pancreas is an investigational device limited by Federal (or United States) law to investigational use. Not available for sale. Dr. Ed Damiano, President & CEO of Beta...
NCQA White Paper Recommends Diabetes Care Overhaul
February 16, 2022 06:00 ET | NCQA
WASHINGTON, Feb. 16, 2022 (GLOBE NEWSWIRE) -- A new white paper released by the National Committee for Quality Assurance (NCQA) and titled Digital Quality Summit White Paper: Rethinking Diabetes...